# DCRI **PEDIATRICS**

As a mission-driven organization, the DCRI is committed to developing and sharing knowledge through innovative clinical research that advances child health. The DCRI conducts pediatric clinical research on an unprecedented scale, enrolling tens of thousands of children worldwide in our studies — harnessing DCRI's reach in order to provide concrete answers to the most important questions in pediatric medicine.

DCRI's pediatric research experience ranges from pharmacokinetic studies in neonates to large, multicenter trials and outcomes studies in every developmental life stage. Our faculty are renowned, experienced researchers in all of the most crucial therapeutic areas and are also practicing physicians, overseeing the implementation of newfound evidence into daily clinical practice. At the DCRI, we strive to be the most impactful pediatric clinical research program in the country, improving research and care for the benefit of our youngest patients.

# TRIALS

- Protocol development
- Regulatory compliance
- Network collaboration
- Rapid-start network of pediatric sites
- Streamlined contracting process
- Feasibility assessments
- Government- and industry-funded
- Master and opportunistic protocols
- Direct-to-family trials
- Real-world data (including regulatorygrade registries)

#### THOUGHT LEADERSHIP

- Internationally recognized faculty
- Trialists and therapeutic
  area leaders
- Faculty with FDA employment in pediatric therapeutics
- Domestic and global experience
- Family and patient engagement
- Coordinating center leadership (e.g., ECHO, PTN, Global PCTN, TIC/TIN)

Duke Clinical Research Institute

• COVID-19 research (e.g., RADx-UP)

# **OPERATIONS**

- Pediatric operational experts
- Long-term site relationships
- Study design and feasibility
- Data and Safety Monitoring Board services
- Safety surveillance
- Pediatric-specific case report forms
- Clinical event adjudication
- Health Services Research
- Dedicated participant engagement program

#### PEDIATRIC CLINICAL PHARMACOLOGY

- Clinical trial simulation and trial design
- Clinical pharmacology from newborns to adolescents
- Intense, sparse, and opportunistic PK sampling
- Population PK/PD and physiologicallybased PK/PD modeling
- Ultra-low volume and dried matrix bioanalyses
- Regulatory compliant analyses and reports

Measured Answers to Pediatric Dosing Questions

# **Therapeutic Areas**

Analgesia and Anesthesia

Cardiology

Critical Care

Dermatology

Gastroenterology

Infectious Disease

Neonatology

Nephrology

Neurology

Primary Care

Psychiatry

Pulmonology

Rheumatology

FROM THOUGHT LEADERSHIP TO CLINICAL PRACTICE












# Find out more about **DCRI Pediatrics.**

Taylor M. Nguyen Associate Director, Grants and **Proposal Services** 919-668-8093 taylor.nguyen@duke.edu

# dcri.org/pediatrics



# DCRI PEDIATRICS

# NUMBERS THAT MATTER



FDA submissions

FACULTY

Disease

Sarah Armstrong, MD: Obesity

Stephen Balevic, MD: Rheumatology

Mara Becker, MD, MSCE: Rheumatology

Danny Benjamin, MD, PhD, MPH: Infectious Disease

Michael Cohen-Wolkowiez, MD, PhD: Infectious

Rachel Greenberg, MD, MHS: Neonatology

Chi Hornik, MD, PhD, MPH: Critical Care

Kevin Hill, MD: Cardiology

pediatric trials



pediatric-specific PK/PD analyses

250+ pediatric sites



Christoph Hornik, MD, PhD, MPH: Cardiology Karan Kumar, MD: Critical Care Priya Kishnani, MD, MBBS: Genetics Jason Lang, MD, MPH: Pulmonology Jennifer Li, MD: Cardiology Laura Schanberg, MD: Rheumatology Brian Smith, MD, MPH, MHS: Neonatology Charlene Wong, MD, MSHP: Health Services Research Kanecia Zimmerman, MD, MPH: Critical Care



FROM THOUGHT LEADERSHIP